Explore Our Services
What We Offer
Keystone Biologics Advisory provides principal-led CMC and regulatory advice for complex biologics, including cell and gene therapies. We support programs at every stage, from early discovery and investor readiness, through first-in-human trials in Australia and the US, to BLA submission.
Every engagement is tailored to your candidate, your stage of development and your next milestone.
Early discovery and preclinical: see Discovery to FIH Readiness and Target Product Profile
Preparing for clinical trials: see INTERACT, Pre-IND Meetings, IND and BLA, and Regulatory Strategy
Clinical development to licensure: see Strategic CMC Advisory Services
Our Services
TPP · CTN · Pre-IND Meetings · IND · BLA · CMC Advisory · Regulatory Strategy · Cell and Gene Therapies · INTERACT ·
TPP · CTN · Pre-IND Meetings · IND · BLA · CMC Advisory · Regulatory Strategy · Cell and Gene Therapies · INTERACT ·
-
The CMC and regulatory decisions made before the first clinical trial often determine how quickly, and at what cost, a program reaches the clinic. Keystone Biologics Advisory works with founders, research institutes and investors from the earliest stages of development. We help them understand the development path for their candidate and identify risks while they are still inexpensive to address.
We provide practical, phase-appropriate advice for complex biologics, including cell and gene therapies, so that early programs are built on a sound CMC foundation. Our goal is a candidate that is credible to investors, ready for regulators and on a clear path to first-in-human (FIH) trials. That path may run through Australia's Clinical Trial Notification (CTN) scheme, an FDA IND, or both.
Our core service offerings include:
Development Path Assessment: An early evaluation of your candidate's CMC and regulatory requirements, identifying critical steps, timelines and potential obstacles on the way to the clinic.
Investor Readiness and Due Diligence Support: Preparing a clear, defensible CMC and regulatory story for fundraising, and supporting founders through investor due diligence. For investors, independent CMC assessment of prospective portfolio programs.
CMC Gap Analysis: A structured review of existing data, processes and documentation against FIH expectations, with a prioritised plan to close the gaps.
Manufacturing and CDMO Strategy: Guidance on process development, choosing a manufacturing partner and technology transfer, including the specialised requirements of viral vectors, cell-based products and other advanced therapies.
Analytical and Characterisation Planning: Defining early critical quality attributes, potency assay strategy and the analytical methods needed to support FIH release and stability.
FIH Regulatory Pathway Planning: Mapping the most efficient route to first-in-human trials across Australian (TGA and CTN) and US (FDA pre-IND and IND) pathways, including how to position early clinical data for later international submissions.
Institute and Spinout Advisory: Supporting research institutes and their commercialisation teams to assess the development path for their assets before spinout or licensing, and to strengthen their value to commercial partners.
-
A well-executed TPP serves as the strategic roadmap for a drug development program. It is an essential foundational document that aligns internal goals and facilitates productive interactions with regulatory agencies.
Keystone Biologics Advisory collaborates closely with clients to architect the TPP. Through in-depth consultation, we help determine the minimal and preferred acceptance criteria for your medicinal product, ensuring every stage of development is driven by the desired clinical and commercial outcome.
-
Strategic FDA Submissions and Authoring
Keystone Biologics Advisory provides end-to-end support for FDA regulatory submissions, ensuring technical data is translated into a compelling and compliant narrative. We specialise in authoring and reviewing CMC content for INTERACT and pre-IND meeting packages, and Module 3 (CMC) for IND applications and BLA submissions.INTERACT and Pre-IND Engagement
Early, strategic engagement with the FDA is critical to de-risking your development program. We provide expert guidance through the entire INTERACT and pre-IND process:Strategic Advising: Developing a targeted regulatory strategy and identifying critical questions for the agency.
Document Authoring: Preparing the INTERACT and/or pre-IND meeting request and comprehensive briefing book.
Agency Interaction: Providing high-level support and attendance during FDA meetings to ensure productive dialogue.
IND and BLA Submissions
We navigate the complexities of Module 3 to build robust, phase-appropriate dossiers that align with the current FDA guidance.Regulatory Readiness: Conducting comprehensive gap analyses of your CMC documentation to identify and remediate risks before submission.
Technical Authoring: Full authoring of manufacturing processes, analytical controls, and risk-mitigation strategies.
Lifecycle Strategy: Proposing regulatory pathways that facilitate a smooth transition from IND-stage development to final BLA licensure.
Our goal is to facilitate timely, strategic engagement with the FDA—positioning your program for successful clinical initiation and BLA approval.
-
Keystone Biologics Advisory provides principal-led CMC counsel across the development lifecycle, from the start of first-in-human (FIH) trials through clinical development to BLA submission.
We work with clients to design phase-appropriate CMC programs. Our strategic, risk-based approach means early-stage programs meet regulatory expectations without unnecessary cost. For later-stage programs, we guide comparability exercises that bridge manufacturing changes and keep the path to licensure clear.
Our core service offerings include:
CMC Drug Development Plans: Integrated, end-to-end CMC roadmaps tailored to your candidate's profile, aligning technical milestones with regulatory expectations from early phase through to commercialisation.
Control Strategy and Specifications: Establishing phase-appropriate manufacturing and analytical controls, with scientifically justified specifications that reflect current regulatory expectations for quality and characterisation.
Comparability and Bridging: Designing robust, data-driven comparability protocols to bridge process changes, scale-up and site transfers throughout development.
Stability and Shelf-Life: Designing stability protocols and reviewing data to support shelf-life justifications for clinical and commercial products.
CMC Gap Analysis for BLA: Identifying and fixing technical and documentation gaps well ahead of BLA submission.
-
Keystone Biologics Advisory works with clients to build a regulatory strategy that supports the efficient execution of their development program, in Australia, the United States or both.
Many Australian biotechs begin clinical development locally under the TGA's Clinical Trial Notification (CTN) scheme, then move to the US through a pre-IND meeting and IND. We help clients plan this route from the start, so that CMC data generated for Australian FIH studies also supports later FDA submissions.
We treat expedited programs and designations as more than regulatory milestones. They are strategic levers. Where relevant, we advise on the CMC implications of FDA programs such as Fast Track, Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designation. Accelerated clinical timelines often put the most pressure on manufacturing readiness.
We connect regulatory status with technical execution, so your manufacturing strategy can keep pace with your clinical pathway.
Not sure where to start?
Tell us about your modality and your next milestone, and we'll suggest the most useful first step.